Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+cells
✍ Scribed by A. L. Asher; J. J. Mulé; S. A. Rosenberg
- Book ID
- 104660390
- Publisher
- Springer-Verlag
- Year
- 1989
- Tongue
- English
- Weight
- 427 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
✦ Synopsis
The role of an immune response in recombinant-human-tumor-necrosis-factor(rHTNF)-mediated regression of a weakly immunogenic, MCA-106 sarcoma in vivo was examined. C57BL/6 mice bearing established 10-day s.c. tumor were treated with single i.v. doses (8 p~g) of rHTNF, rHTNF administration resulted in marked hemorrhagic necrosis and subsequent regression of tumor in treated mice. Mice cured of MCA-106 sarcoma by rHTNF specifically rejected a subsequent challenge (5 x 105 cells) of the same tumor (P <0.01) but not of the antigenically distinct, syngeneic MCA-105 sarcoma. Tumor bearers were depleted in vivo of selective T-cell subsets by the systemic administration of specific monoclonal antibodies before rHTNF therapy, rHTNF-induced regression, but not hemorrhagic necrosis of the MCA-106 sarcoma was blocked in mice depleted of Lyt-2 + cells, but not of L3T4 + cells. The in vivo role of T-cell subsets in rHTNF-mediated tumor regression is discussed.